N4 Pharma Reports Progress in Gene Delivery Tech
Company Announcements

N4 Pharma Reports Progress in Gene Delivery Tech

N4 Pharma (GB:N4P) has released an update.

N4 Pharma PLC has announced successful preliminary results from its collaboration with SRI International, demonstrating that their novel delivery system, Nuvec®, combined with SRI’s Fox Three Molecular Guidance System, can effectively target and knockdown specific genes. This breakthrough is a key step forward in their project, and the company plans to share more detailed findings and implications with major pharmaceutical firms. N4 Pharma’s goal is to partner with other companies, utilizing Nuvec® or Liptide® to deliver oncology, gene therapy, and vaccine products, with the prospect of earning upfront, milestone, and royalty payments.

For further insights into GB:N4P stock, check out TipRanks’ Stock Analysis page.

Related Articles
TipRanks UK Auto-Generated NewsdeskN4 Pharma Engages Investors with CEO Q&A Session
TipRanks UK Auto-Generated NewsdeskN4 Pharma Showcases Strategic Focus and Growth Plans
TipRanks UK Auto-Generated NewsdeskN4 Pharma Advances in Vaccine and Cancer Delivery
Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App